Operating Expenses
Finance Lease ROU Asset Amortization
Vertex Pharmaceuticals Finance Lease ROU Asset Amortization remained flat by 0.0% to $1.80M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 76.7%, from $7.73M to $1.80M. Over 2 years (FY 2023 to FY 2025), Finance Lease ROU Asset Amortization shows a downward trend with a -58.9% CAGR.
Analysis
StatementIncome Statement
SectionOperating Expenses
First reportedQ1 2023
Last reportedQ4 2025Feb 13, 2026
Metric ID:
glw_finance_lease_rou_amortizationHistorical Data
3 years
| FY'23 | FY'24 | FY'25 | |
|---|---|---|---|
| Value | $42.70M | $30.90M | $7.20M |
| YoY Change | — | -27.6% | -76.7% |
Range$7.20M – $42.70M
CAGR-58.9%
Avg YoY Growth-52.2%
Median YoY Growth-52.2%
Current Streak2+ years decline
Finance Lease ROU Asset Amortization at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's finance lease rou asset amortization?
- Vertex Pharmaceuticals (VRTX) reported finance lease rou asset amortization of $1.80M in Q4 2025.
- How has Vertex Pharmaceuticals's finance lease rou asset amortization changed year-over-year?
- Vertex Pharmaceuticals's finance lease rou asset amortization decreased by 76.7% year-over-year, from $7.73M to $1.80M.
- What is the long-term trend for Vertex Pharmaceuticals's finance lease rou asset amortization?
- Over 2 years (2023 to 2025), Vertex Pharmaceuticals's finance lease rou asset amortization has grown at a -58.9% compound annual growth rate (CAGR), from $42.70M to $7.20M.